DDInter1843 DDInter1376
Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Trandolapril {u} (Compound) resembles {v} (Compound) Mitiglinide
Trandolapril {u} (Compound) treats {v} (Disease) coronary artery disease
Trandolapril {u} (Compound) binds {v} (Gene) ACE
Trandolapril {u} (Compound) causes {v} (Side Effect) Dysgeusia
Trandolapril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darbepoetin alfa
Trandolapril {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium bicarbonate
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iloprost
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pegaspargase
Trandolapril {u} may lead to a major life threatening interaction when taken with {v} Potassium gluconate
Trandolapril {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Trandolapril (Compound) resembles Mitiglinide (Compound)
Trandolapril (Compound) treats coronary artery disease (Disease)
Trandolapril (Compound) binds ACE (Gene)
Trandolapril (Compound) causes Dysgeusia (Side Effect)
Trandolapril may cause a minor interaction that can limit clinical effects when taken with Darbepoetin alfa
Trandolapril may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Trandolapril may lead to a major life threatening interaction when taken with Potassium gluconate
Trandolapril (Compound) resembles Nateglinide (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide